Trial Outcomes & Findings for Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment (NCT NCT02367872)

Results Overview

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

48 participants

Primary outcome timeframe

Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Results posted on

2017-11-06

Participant Flow

Participants took part in the study at 4 investigative sites in Japan from 1 March 2015 to 10 June 2016.

Participants with normal renal (1R) and hepatic (1H) function; those who had historical diagnosis of renal (mild \[2R\], moderate \[3R\], severe or end-stage renal failure with no hemodialysis \[4R\], end-stage renal failure \[with hemodialysis\] \[5R\]); hepatic impairment (mild \[2H\] and moderate \[3H\]) were enrolled to receive TAK-272 40 milligram (mg).

Participant milestones

Participant milestones
Measure	Cohort 1R: Normal Renal Function Participants with normal renal function (estimated glomerular filtration rate \[eGFR\] greater than or equal to \[\>=\] 90 milliliter per minute per 1.73 square meter \[mL/min/1.73 m\^2\]) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment Participants with mild renal impairment (eGFR \>=60, less than \[\<\] 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R: End-stage Renal Failure (Hemodialysis) Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (dialysis on Day 1 after dosing). After Part 1 follow-up period, then the same participants received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-dialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day of follow up in Part 1.	Cohort 1H: Normal Hepatic Function Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, prothrombin time \[PT\] or prothrombin time international normalized ratio \[INR\], ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Overall Study STARTED	6	6	6	6	6	6	6	6
Overall Study COMPLETED	6	6	6	6	6	6	6	6
Overall Study NOT COMPLETED	0	0	0	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R: End-stage Renal Failure (Hemodialysis) n=6 Participants Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (dialysis on Day 1 after dosing). After Part 1 follow-up period, then the same participants received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-dialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day of follow up in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Total n=48 Participants Total of all reporting groups
Age, Continuous	66.3 years STANDARD_DEVIATION 5.61 • n=5 Participants	59.7 years STANDARD_DEVIATION 8.94 • n=7 Participants	70.2 years STANDARD_DEVIATION 5.53 • n=5 Participants	69.5 years STANDARD_DEVIATION 5.89 • n=4 Participants	71.2 years STANDARD_DEVIATION 6.91 • n=21 Participants	61.0 years STANDARD_DEVIATION 5.73 • n=10 Participants	61.0 years STANDARD_DEVIATION 10.41 • n=115 Participants	61.5 years STANDARD_DEVIATION 8.96 • n=6 Participants	65.0 years STANDARD_DEVIATION 8.23 • n=6 Participants
Sex: Female, Male Female	3 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	1 Participants n=4 Participants	1 Participants n=21 Participants	3 Participants n=10 Participants	2 Participants n=115 Participants	2 Participants n=6 Participants	14 Participants n=6 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	5 Participants n=7 Participants	5 Participants n=5 Participants	5 Participants n=4 Participants	5 Participants n=21 Participants	3 Participants n=10 Participants	4 Participants n=115 Participants	4 Participants n=6 Participants	34 Participants n=6 Participants
Region of Enrollment Japan	6 Participants n=5 Participants	6 Participants n=7 Participants	6 Participants n=5 Participants	6 Participants n=4 Participants	6 Participants n=21 Participants	6 Participants n=10 Participants	6 Participants n=115 Participants	6 Participants n=6 Participants	48 Participants n=6 Participants
Height	157.3 centimeter (cm) STANDARD_DEVIATION 10.91 • n=5 Participants	163.7 centimeter (cm) STANDARD_DEVIATION 9.18 • n=7 Participants	167.7 centimeter (cm) STANDARD_DEVIATION 5.32 • n=5 Participants	159.0 centimeter (cm) STANDARD_DEVIATION 8.63 • n=4 Participants	160.8 centimeter (cm) STANDARD_DEVIATION 5.56 • n=21 Participants	161.2 centimeter (cm) STANDARD_DEVIATION 5.64 • n=10 Participants	160.0 centimeter (cm) STANDARD_DEVIATION 10.20 • n=115 Participants	161.5 centimeter (cm) STANDARD_DEVIATION 11.40 • n=6 Participants	161.4 centimeter (cm) STANDARD_DEVIATION 8.54 • n=6 Participants
Weight	57.58 kilogram (kg) STANDARD_DEVIATION 6.328 • n=5 Participants	59.80 kilogram (kg) STANDARD_DEVIATION 11.726 • n=7 Participants	69.87 kilogram (kg) STANDARD_DEVIATION 5.654 • n=5 Participants	56.48 kilogram (kg) STANDARD_DEVIATION 9.392 • n=4 Participants	60.83 kilogram (kg) STANDARD_DEVIATION 6.982 • n=21 Participants	62.25 kilogram (kg) STANDARD_DEVIATION 6.275 • n=10 Participants	65.08 kilogram (kg) STANDARD_DEVIATION 11.760 • n=115 Participants	69.73 kilogram (kg) STANDARD_DEVIATION 23.171 • n=6 Participants	62.70 kilogram (kg) STANDARD_DEVIATION 11.674 • n=6 Participants
Body Mass Index	23.42 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 2.807 • n=5 Participants	22.12 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 2.289 • n=7 Participants	24.88 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 2.082 • n=5 Participants	22.22 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 2.588 • n=4 Participants	23.62 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 3.242 • n=21 Participants	24.03 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 2.935 • n=10 Participants	25.33 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 3.389 • n=115 Participants	26.03 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 5.581 • n=6 Participants	23.96 kilogram per square meter (kg/m^2) STANDARD_DEVIATION 3.303 • n=6 Participants
Smoking Classification Never smoked	2 Participants n=5 Participants	4 Participants n=7 Participants	3 Participants n=5 Participants	2 Participants n=4 Participants	3 Participants n=21 Participants	2 Participants n=10 Participants	3 Participants n=115 Participants	1 Participants n=6 Participants	20 Participants n=6 Participants
Smoking Classification Current smoker	0 Participants n=5 Participants	1 Participants n=7 Participants	2 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	4 Participants n=6 Participants	10 Participants n=6 Participants
Smoking Classification Ex-smoker	4 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	4 Participants n=4 Participants	2 Participants n=21 Participants	3 Participants n=10 Participants	2 Participants n=115 Participants	1 Participants n=6 Participants	18 Participants n=6 Participants
Alcohol Classification Drinks every day	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	2 Participants n=4 Participants	0 Participants n=21 Participants	2 Participants n=10 Participants	0 Participants n=115 Participants	0 Participants n=6 Participants	6 Participants n=6 Participants
Alcohol Classification Drinks a few days per week	2 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	2 Participants n=6 Participants	9 Participants n=6 Participants
Alcohol Classification Drinks a few days per month	1 Participants n=5 Participants	2 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants	1 Participants n=115 Participants	0 Participants n=6 Participants	7 Participants n=6 Participants
Alcohol Classification Never drinks	2 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	5 Participants n=21 Participants	2 Participants n=10 Participants	4 Participants n=115 Participants	4 Participants n=6 Participants	26 Participants n=6 Participants
Caffeine Classification Yes	5 Participants n=5 Participants	6 Participants n=7 Participants	5 Participants n=5 Participants	6 Participants n=4 Participants	5 Participants n=21 Participants	6 Participants n=10 Participants	3 Participants n=115 Participants	2 Participants n=6 Participants	38 Participants n=6 Participants
Caffeine Classification No	1 Participants n=5 Participants	0 Participants n=7 Participants	1 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	0 Participants n=10 Participants	3 Participants n=115 Participants	4 Participants n=6 Participants	10 Participants n=6 Participants
Estimated Glomerular Filtration Rate (eGFR)	114.8 mL/min/1.73 m^2 STANDARD_DEVIATION 26.03 • n=5 Participants	80.7 mL/min/1.73 m^2 STANDARD_DEVIATION 17.70 • n=7 Participants	54.8 mL/min/1.73 m^2 STANDARD_DEVIATION 9.50 • n=5 Participants	16.3 mL/min/1.73 m^2 STANDARD_DEVIATION 7.61 • n=4 Participants	4.5 mL/min/1.73 m^2 STANDARD_DEVIATION 0.55 • n=21 Participants	115.2 mL/min/1.73 m^2 STANDARD_DEVIATION 14.55 • n=10 Participants	93.7 mL/min/1.73 m^2 STANDARD_DEVIATION 21.63 • n=115 Participants	100.8 mL/min/1.73 m^2 STANDARD_DEVIATION 16.49 • n=6 Participants	72.6 mL/min/1.73 m^2 STANDARD_DEVIATION 43.41 • n=6 Participants
Alpha1 Acid Glycoprotein (AGP)	64.97 milligram per deciliter (mg/dL) STANDARD_DEVIATION 12.065 • n=5 Participants	48.65 milligram per deciliter (mg/dL) STANDARD_DEVIATION 4.809 • n=7 Participants	70.30 milligram per deciliter (mg/dL) STANDARD_DEVIATION 14.936 • n=5 Participants	114.45 milligram per deciliter (mg/dL) STANDARD_DEVIATION 25.029 • n=4 Participants	82.77 milligram per deciliter (mg/dL) STANDARD_DEVIATION 7.104 • n=21 Participants	55.80 milligram per deciliter (mg/dL) STANDARD_DEVIATION 17.694 • n=10 Participants	51.18 milligram per deciliter (mg/dL) STANDARD_DEVIATION 16.328 • n=115 Participants	41.12 milligram per deciliter (mg/dL) STANDARD_DEVIATION 20.282 • n=6 Participants	66.15 milligram per deciliter (mg/dL) STANDARD_DEVIATION 26.757 • n=6 Participants

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Form of TAK-272 (TAK-272F) and Its Metabolite M-I TAK-272F	2951 nanogramhour per milliliter (nghr/mL) Standard Deviation 391.70	1507 nanogramhour per milliliter (nghr/mL) Standard Deviation 952.72	3481 nanogramhour per milliliter (nghr/mL) Standard Deviation 797.67	8053 nanogramhour per milliliter (nghr/mL) Standard Deviation 2964.7	4579 nanogramhour per milliliter (nghr/mL) Standard Deviation 1091.2	5409 nanogramhour per milliliter (nghr/mL) Standard Deviation 1343.0	2269 nanogramhour per milliliter (nghr/mL) Standard Deviation 366.43	2307 nanogramhour per milliliter (nghr/mL) Standard Deviation 750.08	3085 nanogramhour per milliliter (nghr/mL) Standard Deviation 1551.3
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Form of TAK-272 (TAK-272F) and Its Metabolite M-I M-I	50.66 nanogramhour per milliliter (nghr/mL) Standard Deviation 27.097	31.58 nanogramhour per milliliter (nghr/mL) Standard Deviation 13.765	47.22 nanogramhour per milliliter (nghr/mL) Standard Deviation 18.319	138.9 nanogramhour per milliliter (nghr/mL) Standard Deviation 89.619	104.3 nanogramhour per milliliter (nghr/mL) Standard Deviation 20.684	132.3 nanogramhour per milliliter (nghr/mL) Standard Deviation 40.166	33.95 nanogramhour per milliliter (nghr/mL) Standard Deviation 13.432	38.18 nanogramhour per milliliter (nghr/mL) Standard Deviation 14.860	60.01 nanogramhour per milliliter (nghr/mL) Standard Deviation 27.427

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Cmax: Maximum Observed Plasma Concentration for TAK-272F and Its Metabolite M-I TAK-272F	753.5 nanogram per milliliter (ng/mL) Standard Deviation 211.81	432.2 nanogram per milliliter (ng/mL) Standard Deviation 248.57	580.5 nanogram per milliliter (ng/mL) Standard Deviation 312.90	1555 nanogram per milliliter (ng/mL) Standard Deviation 303.45	1061 nanogram per milliliter (ng/mL) Standard Deviation 222.54	1078 nanogram per milliliter (ng/mL) Standard Deviation 417.38	522.8 nanogram per milliliter (ng/mL) Standard Deviation 111.65	446.0 nanogram per milliliter (ng/mL) Standard Deviation 198.78	688.1 nanogram per milliliter (ng/mL) Standard Deviation 339.69
Cmax: Maximum Observed Plasma Concentration for TAK-272F and Its Metabolite M-I M-I	20.08 nanogram per milliliter (ng/mL) Standard Deviation 11.909	14.13 nanogram per milliliter (ng/mL) Standard Deviation 7.0952	11.05 nanogram per milliliter (ng/mL) Standard Deviation 7.9919	25.30 nanogram per milliliter (ng/mL) Standard Deviation 13.442	19.86 nanogram per milliliter (ng/mL) Standard Deviation 5.6056	20.87 nanogram per milliliter (ng/mL) Standard Deviation 3.5431	12.45 nanogram per milliliter (ng/mL) Standard Deviation 8.8158	11.45 nanogram per milliliter (ng/mL) Standard Deviation 6.2582	17.34 nanogram per milliliter (ng/mL) Standard Deviation 6.6026

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-272F and Its Metabolite M-I TAK-272F	2971 ng*hr/mL Standard Deviation 393.33	1527 ng*hr/mL Standard Deviation 953.59	3519 ng*hr/mL Standard Deviation 812.10	8106 ng*hr/mL Standard Deviation 3004.0	4647 ng*hr/mL Standard Deviation 1101.8	5471 ng*hr/mL Standard Deviation 1342.1	2289 ng*hr/mL Standard Deviation 368.39	2326 ng*hr/mL Standard Deviation 746.40	3126 ng*hr/mL Standard Deviation 1575.2
AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-272F and Its Metabolite M-I M-I	62.32 ng*hr/mL Standard Deviation 32.579	36.87 ng*hr/mL Standard Deviation 15.778	60.47 ng*hr/mL Standard Deviation 21.246	162.0 ng*hr/mL Standard Deviation 99.759	129.6 ng*hr/mL Standard Deviation 23.022	198.8 ng*hr/mL Standard Deviation 95.110	38.84 ng*hr/mL Standard Deviation 15.615	50.52 ng*hr/mL Standard Deviation 16.916	74.82 ng*hr/mL Standard Deviation 31.470

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

AUClast,u is the area under the concentration-time curve of the unbound drug in plasma over the time interval from 0 to time of last quantifiable post-dose of TAK-272.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
AUClast,u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration for TAK-272F	138.7 ng*hr/mL Standard Deviation 72.422	83.51 ng*hr/mL Standard Deviation 40.288	135.0 ng*hr/mL Standard Deviation 16.105	154.7 ng*hr/mL Standard Deviation 55.009	162.9 ng*hr/mL Standard Deviation 40.127	192.4 ng*hr/mL Standard Deviation 55.731	107.7 ng*hr/mL Standard Deviation 17.583	145.5 ng*hr/mL Standard Deviation 82.297	348.5 ng*hr/mL Standard Deviation 102.16

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

Cmax,u is the peak unbound plasma concentration of a drug after administration, obtained directly from the unbound plasma concentration-time curve.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Cmax,u: Maximum Unbound Plasma Concentration for TAK-272F	35.38 ng/mL Standard Deviation 20.053	23.92 ng/mL Standard Deviation 12.222	22.54 ng/mL Standard Deviation 10.180	29.88 ng/mL Standard Deviation 5.8353	37.76 ng/mL Standard Deviation 11.566	38.41 ng/mL Standard Deviation 22.002	24.82 ng/mL Standard Deviation 7.1225	28.11 ng/mL Standard Deviation 17.659	77.66 ng/mL Standard Deviation 23.421

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

AUC∞,u is the area under the concentration-time curve of the unbound drug in plasma over the time interval from 0 to infinity of TAK-272.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
AUC∞,u: Area Under the Unbound Plasma Concentration-time Curve From Time 0 to Infinity for TAK-272F	139.3 ng*hr/mL Standard Deviation 73.070	84.51 ng*hr/mL Standard Deviation 40.355	136.5 ng*hr/mL Standard Deviation 16.537	155.5 ng*hr/mL Standard Deviation 56.099	165.1 ng*hr/mL Standard Deviation 39.885	194.6 ng*hr/mL Standard Deviation 55.238	108.5 ng*hr/mL Standard Deviation 17.885	146.5 ng*hr/mL Standard Deviation 82.800	352.9 ng*hr/mL Standard Deviation 103.09

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-272F and Its Metabolite M-I TAK-272F	0.7500 hour Interval 0.5 to 1.5	0.5000 hour Interval 0.5 to 1.5	1.000 hour Interval 0.5 to 3.0	1.000 hour Interval 0.5 to 1.5	0.7250 hour Interval 0.417 to 0.95	0.9815 hour Interval 0.45 to 1.43	1.000 hour Interval 0.5 to 1.0	0.5170 hour Interval 0.5 to 1.0	0.5000 hour Interval 0.5 to 0.5
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-272F and Its Metabolite M-I M-I	0.7500 hour Interval 0.5 to 1.0	0.7500 hour Interval 0.5 to 1.5	0.7500 hour Interval 0.5 to 1.5	1.000 hour Interval 0.5 to 1.5	0.7250 hour Interval 0.417 to 0.95	0.9250 hour Interval 0.45 to 1.42	1.000 hour Interval 0.5 to 1.0	1.000 hour Interval 0.5 to 1.0	0.5000 hour Interval 0.5 to 1.0

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Apparent Clearance (CL/F) for TAK-272F	13.57 liter per hour (L/hr) Standard Deviation 1.8565 • Interval 0.5 to 1.5	28.05 liter per hour (L/hr) Standard Deviation 9.3870 • Interval 0.5 to 1.5	11.63 liter per hour (L/hr) Standard Deviation 2.6246 • Interval 0.5 to 3.0	5.290 liter per hour (L/hr) Standard Deviation 2.3246 • Interval 0.5 to 1.5	8.955 liter per hour (L/hr) Standard Deviation 3.0987	7.535 liter per hour (L/hr) Standard Deviation 2.1430	17.68 liter per hour (L/hr) Standard Deviation 3.1682	17.83 liter per hour (L/hr) Standard Deviation 5.0433	13.70 liter per hour (L/hr) Standard Deviation 5.1084

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (0.5, 1, 1.5, 2, 3, 4, 5, 8, 10, 12, 14, 24, 36, 48, 72, 96, 120 hours post dose; up to 120 hours) post-dose

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

CLu/F is the apparent clearance for unbound drug after extravascular administration of TAK-272.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
CLu/F: Apparent Clearance for Unbound Drug After Extravascular Administration for TAK-272F	315.7 L/hr Standard Deviation 152.20 • Interval 0.5 to 1.0	500.8 L/hr Standard Deviation 163.96 • Interval 0.5 to 1.5	294.7 L/hr Standard Deviation 34.938 • Interval 0.5 to 1.5	271.5 L/hr Standard Deviation 100.55 • Interval 0.5 to 1.5	247.8 L/hr Standard Deviation 60.579	210.2 L/hr Standard Deviation 46.940	372.8 L/hr Standard Deviation 66.949	301.8 L/hr Standard Deviation 139.68	117.3 L/hr Standard Deviation 33.417

PRIMARY outcome

Timeframe: Day 1: Pre-dose and at multiple time points (4, 8, 12, 24, 36, 48, 72 hours post dose; up to 72 hours) post-dose

Population: The urine PK analysis population where urinary excretion data on Day 1 was available. The urine PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for urine PK.

Urinary excretion ratio (percentage \[%\] of dose) of TAK-272 and its metabolite M-I in urine was calculated for each participant.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=5 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Cumulative Urinary Excretion Ratio of TAK-272F and Its Metabolite M-I From 0 to 72 Hours Post-dose in Cohorts 1R, 2R, 3R, 4R, 1H, 2H and 3H TAK-272F	13.227 percentage of dose Standard Deviation 1.3321	10.710 percentage of dose Standard Deviation 3.2216	12.820 percentage of dose Standard Deviation 2.6621	4.947 percentage of dose Standard Deviation 3.3152	13.980 percentage of dose Standard Deviation 5.0380	15.205 percentage of dose Standard Deviation 2.6194	21.222 percentage of dose Standard Deviation 4.9429	—	—
Cumulative Urinary Excretion Ratio of TAK-272F and Its Metabolite M-I From 0 to 72 Hours Post-dose in Cohorts 1R, 2R, 3R, 4R, 1H, 2H and 3H M-I	0.558 percentage of dose Standard Deviation 0.2596	0.477 percentage of dose Standard Deviation 0.2017	0.284 percentage of dose Standard Deviation 0.0598	0.072 percentage of dose Standard Deviation 0.0462	0.453 percentage of dose Standard Deviation 0.1515	0.557 percentage of dose Standard Deviation 0.1672	0.788 percentage of dose Standard Deviation 0.3352	—	—

PRIMARY outcome

Timeframe: Baseline

Population: The plasma PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.

Plasma protein binding rate was the percentage of unbound fraction of TAK-272F in plasma protein.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Plasma Protein Binding Rate of TAK-272F in Cohorts 1R, 2R, 3R, 4R, 5R, 1H, 2H and 3H	5.298 % of unbound fraction of TAK-272F Standard Deviation 3.1279	5.597 % of unbound fraction of TAK-272F Standard Deviation 0.88260	3.970 % of unbound fraction of TAK-272F Standard Deviation 0.88091	1.948 % of unbound fraction of TAK-272F Standard Deviation 0.35549	3.598 % of unbound fraction of TAK-272F Standard Deviation 0.59734	4.800 % of unbound fraction of TAK-272F Standard Deviation 0.77095	7.177 % of unbound fraction of TAK-272F Standard Deviation 4.0484	12.82 % of unbound fraction of TAK-272F Standard Deviation 6.5481	—

PRIMARY outcome

Timeframe: Day 1: Pre-dose, up to 6 hours post-dose

Population: The dialysate PK set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for dialysate PK.

Excretion ratio (% of dose) of TAK-272F in dialysis fluid was calculated for each participant.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Excretion Ratio of TAK-272F in Dialysate in Cohort 5R	3.110 percentage of dose Standard Deviation 0.8911	—	—	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Baseline up to Day 8 of each Cohort

Population: The safety analysis set included all participants who were treated with at least 1 dose of study drug.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAE)	1 participants	1 participants	1 participants	2 participants	2 participants	1 participants	1 participants	1 participants	3 participants

SECONDARY outcome

Timeframe: Baseline up to Day 8 of each Cohort

Population: The safety analysis set included all participants who were treated with at least 1 dose of study drug.

Number of participants with TEAE related to vital signs was reported in this outcome measure. The related event to report was only "Blood Pressure Decreased" throughout this study.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Number of Participants With TEAE Related to Vital Signs	0 participants	0 participants	0 participants	1 participants	1 participants	0 participants	0 participants	0 participants	1 participants

SECONDARY outcome

Timeframe: Baseline up to Day 8 of each Cohort

Population: The safety analysis set included all participants who were treated with at least 1 dose of study drug.

Number of participants with TEAE related to body weight was reported in this outcome measure. There were no events to report as TEAE related to body weight throughout this study.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Number of Participants With TEAE Related to Body Weight	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants

SECONDARY outcome

Timeframe: Baseline up to Day 8 of each Cohort

Population: The safety analysis set included all participants who were treated with at least 1 dose of study drug.

Number of participants with TEAE related to ECG was reported in this outcome measure. There were no events to report as TEAE related to ECG throughout this study.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Number of Participants With TEAE Related to 12-lead Electrocardiograms (ECG)	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants	0 participants

SECONDARY outcome

Timeframe: Baseline up to Day 8 of each Cohort

Population: The safety analysis set included all participants who were treated with at least 1 dose of study drug.

Number of participants with TEAE related to laboratory tests was reported in this outcome measure. The related event to report was only "Alanine Aminotransferase Increased" throughout this study.

Outcome measures

Outcome measures
Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Number of Participants With TEAE Related to Laboratory Tests	0 participants	1 participants	0 participants	0 participants	0 participants	0 participants	1 participants	0 participants	0 participants

Adverse Events

Cohort 1R: Normal Renal Function

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Cohort 2R: Mild Renal Impairment

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Cohort 3R: Moderate Renal Impairment

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis)

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis)

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis)

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Cohort 1H: Normal Hepatic Function

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Cohort 2H: Mild Hepatic Impairment

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Cohort 3H: Moderate Hepatic Impairment

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Cohort 1R: Normal Renal Function n=6 participants at risk Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 participants at risk Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 participants at risk Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 participants at risk Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 participants at risk Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 participants at risk Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 participants at risk Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 participants at risk Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 participants at risk Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
Blood and lymphatic system disorders Haemorrhagic anaemia	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Gastrointestinal disorders Gastroduodenal ulcer	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Gastrointestinal disorders Toothache	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Gastrointestinal disorders Vomiting	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Infections and infestations Pharyngitis	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Injury, poisoning and procedural complications Contusion	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Injury, poisoning and procedural complications Dumping syndrome	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Injury, poisoning and procedural complications Fall	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Investigations Blood pressure decreased	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Investigations Alanine aminotransferase increased	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Nervous system disorders Headache	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Vascular disorders Orthostatic hypotension	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	16.7% 1/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.	0.00% 0/6 • Treatment-emergent adverse events are adverse events that started after the first dose of study drug up to Day 8 of each Cohort At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.

Additional Information

Medical Director

Takeda

Phone: +1-877-825-3327

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda's sole discretion.
Publication restrictions are in place

Restriction type: OTHER

Measure	Cohort 1R: Normal Renal Function n=6 Participants Participants with normal renal function (eGFR\>=90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2R: Mild Renal Impairment n=6 Participants Participants with mild renal impairment (eGFR \>=60,\< 90 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 3R: Moderate Renal Impairment n=6 Participants Participants with moderate renal impairment (eGFR \>=30, \<60 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 4R: Severe or End-stage Renal Failure(Non-hemodialysis) n=6 Participants Participants with severe or end-stage renal failure undergoing no hemodialysis (eGFR \<30 mL/min/1.73 m\^2) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 5R-Part 1: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 1 is hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 1 (hemodialysis on Day 1 after dosing).	Cohort 5R-Part 2: End-stage Renal Failure (Hemodialysis) n=6 Participants Part 2 is non-hemodialysis part in the Cohort 5R. Participants with hemodialysis received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period in Part 2 (non-hemodialysis on Day 1). Participants who completed Cohort 5R-Part 1 started Part 2 after completion of 2-day follow up period in Part 1.	Cohort 1H: Normal Hepatic Function n=6 Participants Participants with normal hepatic function received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period.	Cohort 2H: Mild Hepatic Impairment n=6 Participants Participants with mild hepatic impairment (Child-Pugh class A score of 5-6) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.	Cohort 3H: Moderate Hepatic Impairment n=6 Participants Participants with moderate hepatic impairment (Child-Pugh class B score of 7-9) received TAK-272 40 mg, tablets, orally in fasted state, once on Day 1 of a 6-day treatment period with 2-day follow-up period. The Child-Pugh classification assesses the severity of 5 hepatic parameters (total serum bilirubin, serum albumin, PT or INR, ascites and encephalopathy grade) on a scale of 1 (none) to 3 (moderate). Total hepatic impairment score ranges from 5 (mild) to 15 (severe) where higher score indicates more severity.
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Form of TAK-272 (TAK-272F) and Its Metabolite M-I TAK-272F	2951 nanogramhour per milliliter (nghr/mL) Standard Deviation 391.70	1507 nanogramhour per milliliter (nghr/mL) Standard Deviation 952.72	3481 nanogramhour per milliliter (nghr/mL) Standard Deviation 797.67	8053 nanogramhour per milliliter (nghr/mL) Standard Deviation 2964.7	4579 nanogramhour per milliliter (nghr/mL) Standard Deviation 1091.2	5409 nanogramhour per milliliter (nghr/mL) Standard Deviation 1343.0	2269 nanogramhour per milliliter (nghr/mL) Standard Deviation 366.43	2307 nanogramhour per milliliter (nghr/mL) Standard Deviation 750.08	3085 nanogramhour per milliliter (nghr/mL) Standard Deviation 1551.3
AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for Free Form of TAK-272 (TAK-272F) and Its Metabolite M-I M-I	50.66 nanogramhour per milliliter (nghr/mL) Standard Deviation 27.097	31.58 nanogramhour per milliliter (nghr/mL) Standard Deviation 13.765	47.22 nanogramhour per milliliter (nghr/mL) Standard Deviation 18.319	138.9 nanogramhour per milliliter (nghr/mL) Standard Deviation 89.619	104.3 nanogramhour per milliliter (nghr/mL) Standard Deviation 20.684	132.3 nanogramhour per milliliter (nghr/mL) Standard Deviation 40.166	33.95 nanogramhour per milliliter (nghr/mL) Standard Deviation 13.432	38.18 nanogramhour per milliliter (nghr/mL) Standard Deviation 14.860	60.01 nanogramhour per milliliter (nghr/mL) Standard Deviation 27.427